Predictive value of serum IL-17,Endocan and Nesfatin-1 to no-reflow in patients with STEMI after PCI
Xia Chun
Xiong Hui
Dai Wenqin
Huang Xianli
Zhao Chunxia
Zeng Shulin
Abstract：Objective To investigate the predictive value of serum interleukin-17(IL-17),endothelial cell specific molecule-1(Endocan)and Nesfatin-1 to no-reflow in patients with ST-segment elevation myocardial infarction(STEMI)after percutaneous coronary intervention(PCI).Methods STEMI patients(n=150)were chosen from Department of Cardiology in Wuchang Hospital of Wuhan City from Jan.2020 to Jan.2022.The patients with no-reflow after PCI were selected into no-reflow group(n=46),and those with normal complete perfusion were selected into control group(n=104).The risk factors for no-reflow were analyzed,levels of serum IL-17,Endocan and Nesfatin-1 were detected and predictive value of IL-17,Endocan and Nesfatin-1 were analyzed.Results The results of single-factor analysis showed that the differences in gender,smoking,age,heart rate(HR),hypertension,diabetes,hyperlipidemia,diastolic blood pressure(SBP),systolic blood pressure(DBP),triglyceride(TG),total cholesterol(TC),high-density lipoprotein-cholesterol(HDL-C),low-density lipoprotein-cholesterol(LDL-C),platelet count(PLT),white blood cell count(WBC),fibrinogen(FIB),creatine kinase-MB isoenzyme(CK-MB),aspertate aminotransferase(AST),drug-eluting stent(DES)and anterior descending branch infarction had no statistical significance between 2 groups(P>0.05).The differences in left ventricular ejection fraction(LVEF),history of coronary heart disease(CHD),neutrophil/lymphocyte ratio(NLR),C-reactive protein(CRP),cardiac troponin T(cTnT),time from disease onset to reperfusion,lesion length,IL-17,Endocan and Nesfatin-1 had significance between 2 groups(P<0.05).The differences in the total ischemia time,preoperative TIMI grading,mean stent diameter,mean stent length,number of diseased vessels and number of stents had no statistical significance between 2 groups(P>0.05).The multi-factor Logistic regression analysis showed that LVEF,CHD history,NLR,CRP,cTnT,time from disease onset to reperfusion,lesion length,IL-17,Endocan and Nesfatin-1 were risk factors for no-reflow in STEMI patients after PCI(P<0.05).In predicting no-reflow in STEMI patients after PCI,the results of ROC curve analysis showed that AUC of IL-17 was 0.818,sensitivity was 86.70%and specificity was 91.20%,AUC of Endocan was 0.978,sensitivity was 89.60%and specificity was 91.40%,and AUC of Nesfatin-1 was 0.963,sensitivity was 90.70%and specificity was 91.00%.Conclusion The expressions of serum IL-17,Endocan and Nesfatin-1 are abnormal in STEMI patients with no-reflow after PCI,which is related to LVEF,CHD history,NLR,CRP,cTnT,time from disease onset to reperfusion and lesion length,and they are independent risk factors for no-reflow.IL-17,Endocan and Nesfatin-1 can early predict no-reflow occurrence after PCI.
Keywords：ST-segment elevation myocardial infarctionPercutaneous coronary interventionInterleukinEndothelial cell specific molecule-1Nesfatin-1
Publication Date：2024-03-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 343-346 )